Blue Water Vaccines Inc. BWV
We take great care to ensure that the data presented and summarized in this overview for Blue Water Vaccines Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BWV
View allLatest Institutional Activity in BWV
Top Purchases
Top Sells
About BWV
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.
Insider Transactions at BWV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 26
2024
|
Thomas Meier Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,318
+50.0%
|
-
|
|
Sep 26
2024
|
Timothy R. Ramdeen Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,318
+48.83%
|
-
|
|
Sep 26
2024
|
James Sapirstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,318
+48.83%
|
-
|
|
Sep 26
2024
|
Ajit Singh Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,318
+49.42%
|
-
|
|
Sep 26
2024
|
Simon Tarsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,318
+48.83%
|
-
|
|
Sep 24
2024
|
Ralph Schiess Interim CEO & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
489,160
+49.66%
|
-
|
|
Sep 24
2024
|
Christian Bruhlmann Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
428,010
+49.66%
|
-
|
|
Feb 16
2024
|
Ajit Singh Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,125
+50.0%
|
-
|
|
May 31
2023
|
James Sapirstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,360
+50.0%
|
-
|
|
May 31
2023
|
Simon Tarsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,360
+50.0%
|
-
|
|
May 31
2023
|
Timothy R. Ramdeen Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,360
+50.0%
|
-
|
|
May 31
2023
|
Vuk Jeremic Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,360
+50.0%
|
-
|
|
May 09
2023
|
Jon Garfield Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
May 09
2023
|
Joseph Hernandez CEO |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+5.08%
|
-
|
|
May 09
2023
|
Erin Henderson Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+46.19%
|
-
|
|
Apr 10
2023
|
Cincinnati Cornerstone Investors Bwv I, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,200,000
-50.82%
|
-
|
|
Nov 17
2022
|
Cincinnati Cornerstone Investors Bwv I, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
750,000
-24.11%
|
-
|
|
Aug 25
2022
|
Cincinnati Cornerstone Investors Bwv I, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
500,000
-13.85%
|
-
|
|
Aug 22
2022
|
Joseph Hernandez CEO |
SELL
Open market or private sale
|
Direct |
30,269
-1.13%
|
$121,076
$4.1 P/Share
|
|
Aug 19
2022
|
Allan Shaw Director |
SELL
Open market or private sale
|
Direct |
29,636
-100.0%
|
$88,908
$3.94 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 937K shares |
|---|